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Abstract:  
Prostate cancer is one of the most common cancers in men and the global burden of this disease is 
rising. Lifestyle modifications like smoking cessation, exercise and weight control offer opportunities 
to decrease the risk of developing prostate cancer. Early detection of prostate cancer by PSA 
screening remains controversial; yet, changes in PSA threshold, frequency of screening, and addition 
of other biomarkers have potential to minimise overdiagnosis associated with PSA screening. Several 
new biomarkers appear promising in individuals with elevated PSA levels or those diagnosed with 
prostate cancer, these are likely to guide in separating individuals who can be spared of aggressive 
treatment from those who need it. Several pharmacological agents like 5α-reductase inhibitors, 
aspirin etc. have a potential to prevent development of prostate cancer. In this review, we discuss 
the current evidence and research questions regarding prevention, early detection of prostate 
cancer and management of men either at high risk of prostate cancer or diagnosed with low-grade 
prostate cancer. 
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Introduction: 
Prostate cancer is one of the most common 
cancers in men and its incidence continues to 
rise in many countries 1.  Screening for and 
management of early prostate cancer is one 
of the most challenging and controversial 
issues in all of medicine. In this paper, we 
review current evidence regarding risk 
assessment, early detection, and 
management of early prostate cancer and 
identify the key issues still in need of further 
research (figure). Better identification of risk 
factors to guide risk adapted screening and 
preventive interventions emerged as a key 
issue. A particular focus was lifestyle factors 
that are potentially modifiable and preventive 
therapies which might reduce risk. PSA-based 
screening for prostate cancer remains 
controversial and results from the 
CAP/ProtecT trial are eagerly awaited. Much 
work is currently ongoing to evaluate new  
tests which might be offered either as part of 
primary screening, or to help with the triage 
of men with an elevated PSA level and these 
are discussed in some detail. We also examine 
management strategies for low grade cancers 
and men with elevated PSA levels but 
negative biopsies. Lastly, we evaluate new 
tests based on serum markers or tissue from 
needle biopsies, the role of multi-parameter 
MRI and outline the need for better diagnostic 
tools. We conclude with a research agenda of 
areas most in need of further development 
and evaluation. 
Risk factors 
These were separated into 3 groups as non-
modifiable (including known genetic 
mutations / polymorphisms, and where no 
specific gene(s) have yet been identified), 
external exposures, including lifestyle factors 
when modification might be possible, and 
blood based markers, which might be a result 
of a mixture of the above.  
Non-modifiable factors. Paramount among 
these is age. In unscreened populations 
prostate cancer has the steepest age-
incidence curve of all cancers and increases at 
approximately the 6th power of age. Only 25% 
of cancers are diagnosed before the age of 
65y in Europe 1. Racial variation is also 
pronounced, with black men of African 
ancestry in the USA having 58% greater 
incidence and 144% greater mortality rates, 
and Hispanics having 14% lower incidence and 
17% lower mortality rates compared to those 
for white men of European ancestry 2. 
Considerable geographic variation is also 
observed. For example, within Europe, 
incidence and mortality in Sweden is about 
twice that in Spain and 1.5 times that in Italy 
3. Incidence in immigrant populations from 
less developed regions is also lower than 
native Caucasian populations in more 
developed nations 4. Asian Indians/Pakistanis 
living in the USA have a standardised 
incidence ratio (SIR) of 0.54 (95% CI 0.49-0.59) 
compared with native whites 4. However, the 
incidence in these immigrants is considerably 
higher compared to that in their country of 
origin. This could at least partially be due to 
the absence of population screening in their 
country of origin 4. Similar findings for 
immigrant populations in Sweden, have been 
recently reported and this study also 
demonstrated that the differences reduced 
with increasing length of stay 5, suggesting 
that lifestyle is an important component of 
these differences. 
 
Genetic factors. The relative risk of developing 
prostate cancer is higher (RR = 2.48; 95% CI 
2.25-2.74) in men who have a first-degree 
relative with prostate cancer. This risk is 
higher in men under 65 (RR = 2.87; 95% CI 
Search strategy and selection criteria: 
References for this Review were identified 
through searches of PubMed. Publication 
date or language restrictions were not 
applied. Search terms "prostate cancer", 
"risk factors”, "screening", “early 
detection” and "prevention" were used. 
Articles identified through searches of the 
authors’ own files were also considered. 
The final reference list is based on 
originality and relevance to the broad 
scope of this Review. 
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2.21-3.74) compared to older men, and if the 
affected relative was a brother rather than a 
father (RR = 3.14; 95% CI 2.37-4.15) 6. Family 
history is clearly important, but only 35% of 
the familial risk is currently explained by 
known genes. Although rare (about 1 per 
300), a BRCA2 mutation confers up to an 8.6-
fold increased risk in men below 65 years of 
age, and such mutations have also been 
related with aggressive cancer 7, 8. There are 
other rare mutations reported in BRCA1, 
HOXB13, NBS1 and CHEK2 8. The HOXB13 
G84E mutated is the only other identified 
factor with an appreciative relative risk (3-4-
fold) and the abnormal allele frequency is 
about 1.3 – 1.4% 9. 
GWAS studies have uncovered more than 70 
lower penetrance susceptibility loci (per allele 
ORs of 1.1 to 1.3 in general) with much higher 
allele frequencies 8. These are individually of 
little direct value, except for the potential to 
identify mechanism of carcinogenesis, but 
when used collectively in panels may be able 
to help with risk stratification, They appear to 
act multiplicatively, and if so, can identify 1% 
of the population with a 4.7-fold relative risk 
8. 
Other potential familial risk factors for which 
a genetic basis has yet to be determined 
include some types of male pattern baldness 
10 and digit length 11 but they need further 
confirmation, and their value in risk 
stratification remains uncertain.  
External exposure. Both ionizing radiation 12 
and UV radiation from sun exposure 13 have 
been linked to prostate cancer, but further 
confirmation and more detailed risk estimates 
are needed. There have also been some 
reports of increased risk in individuals 
exposed to cadmium, but a high exposure is 
rare, and the risk is at most small, so it has 
rather minimal impact on a public health 
scale.  
Urinary tract infections. Some studies, but not 
all, have suggested that the risk for prostate 
cancer is increased in men with a history of 
urinary tract infections 14. Recent studies have 
provided some evidence for a role of 
Trichomonas vaginalis, whereas the evidence 
for the importance of other agents such as 
human papillomavirus and cytomegalovirus is 
weaker 15. Infections might influence the risk 
for prostate cancer by causing chronic intra-
prostatic inflammation, and pathological 
studies have also suggested that inflammation 
may be involved in the development of 
prostate cancer 16. More research on these 
topics is needed, and currently the role of 
urinary tract infections and chronic 
inflammation in the development of prostate 
cancer remains uncertain. 
Lifestyle factors 
Smoking. Smoking is associated with a 
moderate increase in the risk of prostate 
cancer 17. This association is much stronger 
and the increase more pronounced for 
aggressive or fatal cancers, particularly in 
current or heavy smokers who appear to be at 
a 2-fold or higher risk 18. Current smokers are 
also at a higher risk of prostate cancer-specific 
mortality and recurrence. A stronger 
relationship with aggressive cancers is 
important and suggests that smoking may be 
involved in promoting metastatic spread 18. 
Diet, weight and physical activity. A recent 
overview has suggested that increased BMI is 
associated with an increase in advanced 
prostate cancer but a decrease in localised 
disease 19, which may explain some of the 
conflicting findings in earlier reports. Analysis 
of the Prostate Cancer Prevention Trial (PCPT) 
reported similar findings. No clear links with 
specific dietary factors have been established 
although many items, including red meat, 
dairy protein, dietary fat and coffee 19, have 
been suggested. A sedentary lifestyle has 
been linked to higher PSA in one large survey 
20 and a meta-analysis of 19 cohort and 24 
case-control studies found a small inverse 
relationship between physical activity and 
prostate cancer risk 21. Adult height has also 
been associated with increased risk 22. 
Endogenous hormones. The possible role of 
endogenous hormones in the aetiology of 
prostate cancer has been investigated in 
prospective epidemiological studies. For sex 
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hormones, a pooled analysis of individual 
participant data from 18 studies found no 
significant associations 23, but more data are 
needed to explore the relationship where 
both, decreased overall risk 23 and an 
increased risk of high-grade cancer have been 
reported 24.  For insulin-like growth factors 
(IGFs), a pooled analysis of individual 
participant data from 12 studies showed a 
significant positive association between 
circulating IGF-I and prostate cancer risk 25; 
more data are required on IGF-II and IGF 
binding proteins. 
PSA screening 
The value of PSA screening is a hotly debated 
issue.  Five screening trials have been 
completed, but 3 are not of adequate quality 
to be informative 26. The remaining two are of 
higher methodological quality and are most 
informative. These two large trials, PLCO 27 
and ERSPC 28, have reported apparently 
different results 29. However this may be 
explained at least in part by differences in 
their design. The PLCO trial in the USA, where 
PSA testing is widespread, can be viewed as a 
trial of opportunistic vs. organised annual 
screening 29. Equal proportions of men in 
control (34.3% once and 9.8% two or more 
times) and screening arms (34.6% once and 
9.4% two or more times) had undergone PSA 
testing within 3 years preceding recruitment 
in the trial 27. And although the rate of PSA 
testing in control group (40%) was lower than 
that in screening group (85%) in the first year, 
it increased to 52% in the sixth year. Men 
randomised to intervention arm had a higher 
prostate cancer incidence (RR = 1.12; 95% CI = 
1.07 to 1.17) but no reduction in prostate 
cancer mortality has been seen (RR = 1.09; 
95% CI = 0.87 to 1.36). The observed lack of 
benefit may not be entirely due to 
contamination in the control arm as the 
Figure: Prevention and Early Detection of Prostate Cancer Potential modifiable and non-modifiable risk 
factors, pharmacological agents, early detection and triage strategies for of prostate cancer prevention 
and early detection, many of these are yet to be established. 
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results did not vary by PSA screening status at 
baseline, but those having undergone pre-
recruitment screening had 25% lower 
prostate cancer death rates than those who 
did not. In contrast the European ERSPC trial 
28 examined the role of PSA screening in a 
largely unscreened population (7-30% of 
control men screened during the trial 
depending on trial centre) from 7 countries 
with varying screening and treatment 
strategies. Overall, they found a highly 
significant 21% reduction (rate ratio, 0.79; 
95% CI 0.68 to 0.91; P=0.001) in death from 
prostate cancer in a pre-defined subgroup of 
men aged 55-69 years after 11 years of follow 
up. Comparisons of treatments used in the 
two randomised groups have been conducted 
to see if this could explain these differences 30, 
31. More patients in the screening arm were 
found to be treated by radical prostatectomy 
and more with hormone therapy in the 
control arm, but this was largely explained by 
worse tumour characteristics in the control 
arm, reflecting their later diagnosis 30. The 
authors concluded treatment differences 
could not entirely explain the mortality 
benefit 30. Differences in terms of screening 
interval and follow up protocols also exist 
between the two trials, but it was felt that the 
major difference between the findings of 
these studies could be explained by the high 
screening rates in the controls of PLCO. Other 
3 methodologically lower quality trials did not 
observe any reduction in prostate cancer 
mortality 26. 
The majority of the members (62%) of the 
group agreed that PSA screening does reduce 
death from prostate cancer; others (GA, OWB, 
PHB, LGF, FCH, DI, LMM, HLP, BT, TJW and 
AW) felt that the current evidence is not 
sufficiently conclusive. All agreed that the 
magnitude of the effect was uncertain and 
that there is a substantial degree of 
overdiagnosis and overtreatment, which 
needs to be reduced before 
recommendations for using PSA screening in 
the general population can be made. A third 
major trial (the CAP/ProtecT trial) involving 
450,000 men (ISRCTN92187251 and 
ISRCTN20141217) is due to report its initial 
findings in 2016 and this should help to clarify 
the value of PSA screening. It was agreed that 
death from prostate cancer should be the 
primary endpoint for screening studies. While 
difficulties in ascertainment of cause of death 
exist in older men, overall mortality suffers 
from lack of power due to deaths from 
unrelated cause and the sample size required 
to observe an effect is prohibitively large. 
Every effort should be made to accurately 
identify the specific cause of death. A useful 
secondary endpoint is the development of 
metastatic disease, which can provide more 
powerful and earlier evidence of a screening 
effect provided it is assessed with equal 
thoroughness in both trial arms.  
New triage and screening markers. A major 
focus of research needs to be the 
development of new methods and markers 
which more clearly separate indolent (low-
risk) cancers from aggressive and potentially 
lethal ones, thus enabling conservative 
management of a much larger proportion of 
the cancers found. Ideally this would be 
achieved by non-invasive and relatively cheap 
methods such as additional serum markers 
(such as the Kallikrein proteins) or urinary 
markers (such as PCA3 or TMPRSS-ERG 
fusions). Multi-parametric MRI (mp-MRI) or 
assays that can be performed in needle 
biopsies (such as the CCP score, others) may 
also be useful for safely avoiding radical 
prostatectomy and radiotherapy in a 
proportion of patients and therefore avoiding 
the morbidity associated with these 
treatments.  
Modifications of existing PSA screening 
strategies like changes in screening frequency 
and PSA thresholds have potential to reduce 
harms from screening. Increasing interval 
between PSA tests, from annual testing as in 
the PLCO trial to testing to tests every 2-4 
years as in the ERSPC trial may reduce harms 
from overdiagnosis without much detrimental 
effect on prostate cancer mortality reduction. 
Similarly, some data from population-based 
studies and RCTs like the Prostate Cancer 
Intervention vs. Observation Trial (PIVOT) 
support increasing threshold to define an 
abnormal PSA value to 6-10 ng/mL from 
existing 3-4 ng/mL level 32.  
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Serum and urine markers. Several potential 
improvements on the current PSA assay have 
been developed. Of these the prostate health 
index PHI, which is based on a molecular 
isoform of free PSA 33, is the most developed 
and has been shown to have greater 
specificity than use of total PSA or % free PSA. 
Adding the Kallikrein protein hK2 to PSA 
based markers has also been shown to 
improve the specificity of PSA based assays 34 
but both need further validation in a 
screening context, with a particular focus on 
how they might be integrated into screening 
algorithms and compared against current risk 
calculations.  
Urinary markers need some degree of 
prostatic massage via DRE, to obtain enough 
cells to be sensitive, which limits their role to 
triage men identified to be at increased risk. 
Currently the assays are complicated and 
require a specialist laboratory for their use. 
Two assays have received the most attention. 
PCA3 measures mRNA 35 only produced in 
prostate tissue which is markedly 
overexpressed in prostate cancer cells. PCA3 
is more specific than PSA, which is a measure 
of total prostate volume. Initial reports 
indicate that while it does usefully identify 
cancer, it does not discriminate between low 
risk and aggressive disease 36. A urinary 
marker that detects the fusion of TMPRSS2 
with ERG is also under development and may 
have greater ability to separate aggressive 
from low risk early lesions 37. Measurement of 
gene fusions between ERG and other 
potentially important genes in urine or 
multiplexing of PCA3 and TMPRSS2-ERG with 
other genes like SPINK1 and GOLPH2 is also an 
area of interest. 
Comparative studies have indicated that PHI, 
the 4 marker Kallikrein panel and PCA3 are all 
more accurate than conventional PSA in 
detecting cancer, primarily as a result of 
better specificity 34, 38. PSA levels at ages 
between 40 and 60 have also been shown to 
predict risk of prostate cancer several years 
later and may also help in identifying cancers 
likely to  become metastatic or lead to death 
39, 40. This needs to be investigated further to 
improve screening and triage strategies.  
Methylation markers may also be useful for 
the diagnosis and prognosis of prostate 
cancer, but work is still in an early stage. 
Further research is needed for validation with 
an aim to allow use in needle biopsy 
specimens and ultimately serum or urine 
samples.   
Multi-parametric Magnetic Resonance 
Imaging 
Multi-parametric MRI includes a combination 
of high resolution T2-weighted image and at 
least two functional MRI techniques such as 
diffusion weighted imaging (DWI), dynamic 
contrast enhancement (DCE), MR 
spectroscopy (MRS) to improve specificity 41, 
42. It aims to provide better anatomical 
delineation, improved specificity in 
characterisation of lesions, and a more 
reliable assessment regarding organ-
confinement of the tumour in order to guide 
therapy. A key question is the ability of mp-
MRI to identify which Gleason 6 cancers can 
be safely managed by active surveillance (AS). 
The potential for such use is based on its 
ability to highlight areas of aggressive disease, 
and improve staging by identifying extra-
capsular extension or disease in anterior or 
apical locations, which may not be reliably 
ascertained on digital rectal examination or 
standard systematic biopsies 41. Apart from 
improving planning of curative treatments, 
this is also likely to improve selection of 
patients for AS. The potential role of mp-MRI 
to monitor AS patients also needs to be 
investigated 42.The value of MRI-guided 
biopsies and MRI-transrectal ultrasound 
fusion guided biopsies is emerging and both 
show higher detection rates for significant 
cancer than standard systematic biopsies 42. 
Ongoing trials like Prostate MRI Imaging Study 
(PROMIS; ISRCTN: 16082556) are likely to 
clarify its role in the diagnostic pathway and 
its cost-effectiveness. Incorporation of mp-
MRI in models predicting cancer risk in cases 
with prior negative biopsy also appears 
promising but requires further study 41, 42. 
Markers in needle biopsies. Although done at 
a later stage, progression markers identified in 
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needle biopsies, may still be able to help avoid 
unnecessary radical treatment.  
Ki67 by immunohistochemistry (IHC) is the 
most established marker and has been shown 
to be useful in distinguishing between 
aggressive and indolent prostate cancer 43. 
IHC and Fluorescent in situ Hybridisation 
(FISH) assays for PTEN have also shown some 
promise 44, 45 as has a FISH assay for TMPRSS2-
ERG fusion 46, albeit with conflicting results 47. 
Similarly overexpression of MYC 48 by FISH and 
p53 49 by IHC have also been shown to possess 
some prognostic potential. A four-protein 
signature, PTEN, SMAD4, cyclin D1, and SPP1, 
as assessed by IHC has been found to predict 
biochemical recurrence 50. 
Of far greater prognostic value is a cell cycle 
progression score (Prolaris, Myriad Genetics), 
it has been shown to be predictive of 
outcome in a number of studies in TURP, 
needle biopsy and radical prostatectomy 
specimens 51. As this material contains much 
more tumour than a serum or urinary sample, 
the potential for better assessment exists. 
However issues of inadequate sampling still 
remain for needle biopsies especially when 
few cores are obtained, and the performance 
of these assays when 12 core or template 
biopsies are taken is an important research 
area. Other mRNA marker panels have also 
been explored with some success, often 
containing PTEN, p53 or TMPRSS2-ERG 52;  
Management of men with elevated PSA 
Management of men with elevated PSA levels 
but who have negative biopsies presents 
another important question. Studies 53, 54 have 
shown a high incidence of prostate cancer 
over the subsequent few years of follow up. 
The Göteborg sub-cohort of the ERSPC 
observed a 26% incidence within 4 years 54, 
whereas 10% of such men in PLCO developed 
prostate cancer within 3 years of negative 
biopsy 53. The placebo arm of the Prostate 
Cancer Prevention Trial (PCPT) has also shown 
similarly high positivity rates (15% overall) for 
cancer in biopsies of men with normal PSA 
levels at the end of a 7-year study period 55. 
The role of additional markers like Kallikrein 
panels for triage of such men merits further 
investigation 34. 
Management of low grade prostate cancer 
An equally pressing issue is the management 
of men with low grade (e.g. Gleason score 6) 
cancer. Gleason 6 is a poorly defined entity, 
and its natural history and the appropriate 
active surveillance protocols are ill-defined 
and need to be refined and clinically 
validated.  
The PIVOT trial 32 has shown that for selected 
low risk subgroups, passive observation lead 
to the same prostate cancer mortality as 
radical prostatectomy, and this is a potentially 
important management option. However, the 
SPCG-4 trial, where almost all of diagnoses 
were symptom-driven, reported reductions in 
prostate cancer or all-cause mortality and 
distant metastases with radical prostatectomy 
as compared with observation, but only the 
effect on distant metastases was statistically 
significant in men aged 65 years or more 56. 
Apart from treatment-related morbidity and 
mortality, observation alone also avoids 
biopsy-related morbidity in active 
surveillance. The challenge remains to identify 
as large a subgroup as possible which can be 
safely managed this way. For this purpose 
new markers of aggression need to be 
developed and validated, especially in men  
with Gleason 6 cancer and PSA < 10ng/ml. 
Role of 5α-reductase inhibitors 
Evaluation of the use of 5α-reductase 
inhibitors (5-ARIs) either for prevention or 
management of early disease has produced 
complex outcomes. The PCPT 57 evaluated 
finasteride in men with low PSA (</= 3mg/ml) 
and no evidence of disease. Biopsies were 
recommended if DRE was abnormal or PSA 
adjusted for finasteride effect exceeded 4.0 
ng/ml or at the end of the study. After 7 years 
of follow up a 24.8% reduction (95% CI 18.6-
30.6%) in all prostate cancer was seen, but 
this effect was restricted to a reduction in 
Gleason 6 or below cancers, and an increase 
of 27% in high grade tumours was seen (RR = 
1.27; 95% CI 1.07-1.50). Very similar results 
were seen in the REDUCE trial 58 which 
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evaluated dutasteride, another 5α-reductase 
inhibitor, in a high risk population of men with 
a PSA value between 2.5 – 10ng/ml, but a 
negative initial prostate biopsy. After a four 
year follow up, a 23% reduction in all prostate 
cancer was observed, but again with no effect 
on Gleason 7 or above cancer and an 
increased number of Gleason 10 tumours. 
While both drugs have a beneficial impact on 
benign prostatic disease, the lack of effect on 
high grade cancer has been a major concern. 
Relatively greater sampling by biopsy because 
of smaller total prostate size has been offered 
as an explanation for this 59. Similar to the 
findings in the RCTs, a recent large 
population-based case-control study reported 
significantly decreased risk of cancer with 
Gleason scores 2-7 in men treated with 5-
ARIs; however, in contrast to RCTs, no 
evidence of an increased risk of cancer with 
Gleason scores 8-10 was seen 60. Prevention 
of low risk prostate cancer is potentially 
beneficial by avoiding diagnosis and 
treatment-related harms, and it may even be 
cost-effective 61, but neither drug has been 
approved by the FDA for cancer prevention. 
Recent long-term results from PCPT 
confirmed earlier findings and 15-year overall 
survival rates were similar in both arms even 
though more high-grade prostate cancers 
were diagnosed in the finasteride arm 62. It is 
worth noting however that the trial had 
limited power to detect a difference in overall 
survival. For individuals on 5-alpha-reductase 
inhibitors, clinicians should adjust the PSA 
biopsy thresholds as these agents decrease 
PSA values. Retrospective analysis of the 
REDUCE trial has shown that PSA maintains its 
predictive value for men on dutasteride when 
lower biopsy thresholds are used 63. 
Dutasteride has also been investigated as an 
adjuvant treatment in REDEEM trial of 302 
men (289 evaluable) with Gleason 5-6 cancer 
managed by active surveillance 64. After a 3-
year follow-up, a 38% reduction (HR = 0·62, 
95% CI 0·43-0·89) in progression was seen 
with dutasteride but no metastatic disease or 
prostate cancer related deaths were seen in 
either arm. A large trial with longer follow up 
is needed to fully evaluate role of 5α-
reductase inhibitors in the prevention of 
aggressive prostate cancer. 
Other preventive agents 
Trials of agents found in the diet which were 
thought to have a beneficial impact on 
prostate cancer have been disappointingly 
negative 65. Early randomised studies of the 
role of beta-carotene in those at high risk of 
the lung cancer showed an increase in lung 
cancer, as well as stomach cancer. In a more 
recent study with prostate cancer as the 
primary endpoint, the SELECT trial 66 has 
found that in 35 533 men with PSA < 4ng/ml 
and a negative DRE, neither selenium nor 
vitamin E supplementation had a beneficial 
impact on prostate cancer incidence and an 
increase in incidence was observed with 
vitamin E. 
A short term study of the polyamine synthesis 
inhibitor difluoromethylornithine (DFMO) has 
been completed 67.  It was found to 
significantly lower polyamine content in the 
prostate within one month, and suppression 
of prostate putrescine levels was maintained 
and the rate of prostate growth was 
decreased on a 12-month follow up compared 
with placebo. Further long term follow up 
studies are needed.    
Evidence for other preventive or therapeutic 
interventions is currently limited and comes 
from randomized trials in which prostate 
cancer was a secondary endpoint and from 
epidemiologic studies. The agent with the 
most promising profile is aspirin. Both case-
control and cohort studies 68 suggested a 
small but consistent reduction in incidence of 
approximately 10%. The randomized trials 69 
have suggested a somewhat larger 19% 
reduction (p = 0.12) in mortality, suggesting 
that this benefit is also seen for aggressive 
tumours. This has been corroborated in 
Health Professionals Follow-up Study (HPFS), 
which observed a 16% reduction (HR = 0.84; 
95%CI 0.69-1.02) in lethal prostate cancers 
(metastatic or fatal) 70. These trials have been 
conducted in individuals at average risk for 
prostate cancer - with or without 
cardiovascular risk factors, and further studies 
Accepted for publication in the Lancet Oncology: 
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70211-6/abstract  
9 
 
focused on high risk individuals and those 
with Gleason >7 tumours are needed. There 
are suggestions that one aspect of aspirin’s 
effects is through an anti-platelet mechanism 
to slow metastatic spread and improve 
survival, but effects through other pathways 
have also been proposed 70. Also, a range of 
adjuvant trials in different tumour types 
including prostate cancer are either underway 
(ClinicalTrials.gov Identifiers: NCT00565708 
and NCT01058902) or are being planned. An 
overview of observational studies has 
suggested beneficial effect of statins in 
reducing prostate cancer incidence, and 
particularly advanced prostate cancer 
incidence 71. However, reduction in prostate 
cancer incidence is not seen with long-term 
statin use and also when data from RCTs are 
also considered 72.  Residual confounding due 
to health awareness in statin users and 
screening frequency is likely and the potential 
beneficial effect remains unclear in absence of 
long-term follow-up data; further research 
and long-term follow-up of RCTs are needed. 
Results to date for other dietary supplements 
have not been very promising. Vitamin D 
showed promise in some initial epidemiologic 
studies, but more recent work has been 
negative 73. However several major studies 
are underway and they need to be completed 
before a full conclusion can be reached.  
Lycopene, an open chain carotenoid found in 
cooked tomatoes also showed initial promise, 
but an overview of all randomized controlled 
trials to date has not shown any overall effect 
74, although the data are still sparse. Meta-
analysis of observational evidence indicates 
no overall effect with low/moderate intake, 
but a potential effect with high lycopene 
intake (RR=0.89, 95% CI 0.81-0.98) 75, 
although the evidence is very limited . 
Several other dietary factors are of interest 
including sulforaphane, a naturally occurring 
isothiocyanate, which is found in broccoli and 
other cruciferous vegetables and is currently 
being investigated (ClinicalTrials.gov 
Identifiers: NCT01265953 and NCT00946309). 
 
Research and Policy Agenda. The key research 
issues focus around better biomarkers for 
identification of aggressive disease. A number 
of potential modalities look promising and 
require further development. Of these, 
urinary markers such as PCA3 and TMPRSS2-
ERG are the most developed but still require 
further validation. Use of multi-parametric 
MRI also shows promise for identifying the 
most significant lesion and guiding biopsy 
towards the most aggressive appearing 
region, especially in men with higher PSA 
values. Further studies investigating its role 
are needed. Once a biopsy has been taken, 
expression profile panels such as the CCP 
score offer good prospects for determining 
tumour aggressiveness, and they need to be 
evaluated in a range of contexts. A significant 
proportion of cases with high PSA or cases 
identified as high risk by conventional 
variables do not progress or cause death. 
Biomarkers identifying indolent disease in 
such cases are also needed to identify men 
who can be spared of treatment and resulting 
adverse effects. When better biomarkers 
become available, future etiological studies of 
modifiable risk factors should focus on those 
associated with aggressive prostate cancer. 
Careful consideration of the population most 
like to benefit from screening is also needed. 
In particular men aged greater than 70years 
or younger men with other serious 
comorbidities are not good candidates. 
Lengthening screening interval to every 2-4 
years may also reduce harms without 
significantly reducing benefits. Better primary 
screening markers that improve the specificity 
are also needed and assays such as PHI and 
the 4 marker Kallikrein panel need to be 
rigorously evaluated in the appropriate clinical 
setting. 
In addition, the appropriate treatment and 
management of individuals without cancer 
but at high risk (often due to elevated PSA but 
negative biopsy), with low grade tumours 
(Gleason 6 and PSA < 10 ng/ml) tumours, or 
with a genetic predisposition is an area that 
urgently needs further work. Currently aspirin 
looks to be one of the more promising agents, 
although further studies on dietary 
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supplements including vitamin D, DFMO, 
lycopene and sulforaphane are warranted. 
Further study on the 5-α reductase inhibitors 
will be difficult in the current climate although 
many issues remain unresolved. 
Conclusions: 
Evidence is still uncertain for several of the 
modifiable prostate cancer risk factors. 
However, lifestyle modifications like smoking 
cessation and exercise can decrease the risk 
of developing prostate cancer. 5α-reductase 
inhibitors, although associated with an 
increased number of high-grade prostate 
cancers, reduce overall prostate cancer 
burden. In absence of any detrimental effect 
on survival, these agents can be cost-effective 
in prostate cancer prevention. Several other 
pharmacological agents, e.g. aspirin appear 
promising and need further evaluation in 
clinical trials; many such trials are already 
underway. While PSA screening remains a 
controversial topic, overdiagnosis associated 
with PSA screening can be minimised by one 
or several modifications like changes in the 
PSA threshold, frequency of screening, and 
addition of other biomarkers like Kallikrein 
panel, free-PSA. Prospective evaluation of 
these should remain among top research 
priorities. The role of newer biomarkers like 
urinary PCA3 and TMPRSS2-ERG assays also 
appears promising and needs further 
evaluation in screening setting. Similarly, 
newer methods to distinguish aggressive 
prostate cancers from indolent cancers 
diagnosed during screening are needed and 
biomarkers like Ki67, CCP or imaging methods 
like mp-MRI need further prospective 
evaluation so that these can be incorporated 
in management algorithms to minimise 
overtreatment.  
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